Professional · Issue 3 · 2026-10-04
Prenatal CFTR Modulator Therapy for Fetal Meconium Ileus: Signal of Benefit, but Evidence Remains Preliminary
Editorially reviewed research summaries, context, and limitations.
Vincenzo G Menditto, Giovanni Pomponio, Nicole Caporelli, et al.
Summary: This systematic review and individual patient data (IPD) meta-analysis synthesized 18 studies examining whether CFTR modulator (CFTRm) therapy administered to pregnant women — either carriers or mothers with CF — can prevent or treat fetal meconium ileus (MI). Among 42 fetuses with antenatally diagnosed MI who were exposed to CFTRm, only 12% required surgical intervention. Compared with a historical control cohort, this represented a putative 59.5% absolute risk reduction in surgery. Importantly, none of nine asymptomatic fetuses exposed to CFTRm developed MI. Meta-regression identified earlier diagnosis (second trimester) and treatment duration of at least five weeks as factors associated with better outcomes.
Why it matters: Meconium ileus affects approximately 15–20% of newborns with CF and carries meaningful morbidity, including the need for major abdominal surgery, potential short-gut complications, and prolonged neonatal hospitalization. The possibility that maternal CFTR modulator therapy — primarily elexacaftor/tezacaftor/ivacaftor (ETI) in the cases reported — could reduce or prevent this complication represents a genuinely important clinical question as more women with CF or carriers reach reproductive age in the modulator era. The finding regarding asymptomatic fetuses, if validated, would have immediate implications for prenatal counseling and management, particularly as prenatal genotyping and fetal ultrasound anomaly detection become more routine.
Expert perspective: The authors are appropriately cautious, and the reader should be equally so. The evidence base here is constructed almost entirely from case reports and small observational series — the building blocks of hypothesis generation, not hypothesis confirmation. An IPD meta-analysis is a methodologically sophisticated tool, but pooling 18 small, heterogeneous, largely uncontrolled studies does not transform weak primary evidence into strong evidence.
The comparison with a historical cohort is the most precarious element. Historical controls differ from contemporary exposed patients in genotype distribution, prenatal diagnostic practices, gestational age at detection, access to specialized neonatal surgical care, and — crucially — the likelihood that cases treated with CFTRm in recent years are detected earlier and managed more intensively precisely because clinicians are aware of the potential intervention. This is a profound confounding-by-indication and ascertainment-bias problem that cannot be adequately adjusted away. The 42 fetuses with antenatally diagnosed MI represent an extremely small sample: the 95% CI for the proportion requiring surgery runs from 6% to 25%, and for the absolute risk reduction from 44% to 69% — ranges compatible with a range of clinically quite different realities. The meta-regression findings must be interpreted with maximum caution; fitting a regression model to 42 patients with multiple covariates is prone to overfitting, and the confidence intervals on key odds ratios span two to three orders of magnitude (e.g., OR 15.15, 95% CI 1.41–162.73), signaling high uncertainty rather than precision.
The mechanism by which a drug administered to a carrier mother could affect fetal gut function is not straightforward, and drug levels in fetal tissues, the degree of fetal CFTR modulation achieved, and fetal genotype are relevant variables that are inconsistently reported across the included studies. In summary, this paper provides the best available synthesis of a small and inherently limited literature, and the biological plausibility of benefit is real. The signal justifies prospective study. It does not justify routine clinical recommendations for CFTRm use in carrier mothers solely to prevent fetal MI outside of carefully designed trials or registries with informed consent and systematic follow-up. The authors acknowledge this honestly.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42632793/
---